Tovorafenib

**Semantic type:** Pharmacologic Substance

**Definition:** An orally available inhibitor of wild-type and certain mutant forms of A-Raf, B-Raf and C-Raf protein kinases, with potential antineoplastic activity. Upon administration, tovorafenib inhibits Raf-mediated signal transduction pathways, which may lead to an inhibition of tumor cell growth. Raf protein kinases play a key role in the RAF/MEK/ERK signaling pathway, which is often deregulated in human cancers and plays a key role in tumor cell proliferation and survival.

**Synonyms:** - (R)-2-(1-(6-amino-5-chloropyrimidine-4-carboxamido)ethyl)-N-(5-chloro-4-(trifluoromethyl)pyridin-2-yl)thiazole-5-carboxamide - BIIB 024 - BIIB-024 - BIIB024 - DAY 101 - DAY-101 - DAY101 - MLN 2480 - MLN-2480 - MLN2480 - Ojemda - TAK 580 - TAK-580 - TAK580 - TOVORAFENIB - pan-RAF Kinase Inhibitor DAY101